AxoGen (NASDAQ: AXGN) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $28.1 million versus the consensus estimate of $29.23 million.

“I am pleased with our fourth quarter and full-year performance. We delivered solid revenue growth and continued to make progress rebalancing and refocusing our commercial operation toward our largest market opportunity, extremity trauma,” commented Karen Zaderej, chairman, CEO, and president of Axogen, Inc. “I am confident that we have the right commercial strategy in place to drive strong surgeon adoption of our technology as we continue to develop the nerve repair market.”

GUIDANCE:

AxoGen sees Q1 2020 revenue of $124-128 million, versus the consensus of $131.75 million.

For earnings history and earnings-related data on AxoGen (AXGN) click here.